International health activists and civil society organisations have launched a scathing critique of pharmaceutical giant Gilead Sciences and the US government. They say that Lenacapavir is in short supply and woefully inadequate to slow Africa’s epidemic. The backlash follows a joint announcement earlier this week by the US government and the Global Fund to Fight HIV/Aids, Tuberculosis and Malaria regarding…